Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute Leukemia

NCT02822326 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Acute Leukemia

Interventions

BIOLOGICAL: CD19-CAR-T2 Cells

Sponsor

Guangdong Provincial People's Hospital

Collaborators

[object Object]
[object Object]